NCT06314919 A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib
| NCT ID | NCT06314919 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Condition | Primary Hypercholesterolemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 8,606 participants |
| Start Date | 2024-03-15 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 8,606 participants in total. It began in 2024-03-15 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition
Eligibility Criteria
Inclusion Criteria: * Those who taking statins or statins and ezetimibe in addition to dietary and exercise therapy for primary hypercholesterolemia or mixed hyperlipidemia * Those who are judged to need administration of a fixed-dose combination of pitavastatin/ezetimibe for change of statin's formulation or change of statin's dose, addition of ezetimibe Exclusion Criteria: * Those who are taking a fixed-dose combination of pitavastatin/ezetimibe at study enrollment * Those with hypersensitivity reactions or relevant medical history to pitavastatin or ezetimibe * Those who have been administered an investigational product within 12 weeks of the enrollment date or are planning to participate in another clinical trial during this study participation period.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06314919 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Primary Hypercholesterolemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06314919 currently recruiting?
Yes, NCT06314919 is actively recruiting participants. Contact the research team at syoh@boryung.co.kr for enrollment information.
Where is the NCT06314919 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06314919 clinical trial?
NCT06314919 is sponsored by Boryung Pharmaceutical Co., Ltd. The trial plans to enroll 8,606 participants.